BOSTON & PERTH, Australia--(BUSINESS WIRE)--Global bio-nanotech company pSivida Limited (NASDAQ:PSDV)(ASX:PSD)(Xetra:PSI) today announced that it has entered into a collaboration with a global electronics and technology company to evaluate its BioSilicon™ technology (nano-structured silicon) for the development of transdermal drug delivery systems. The collaboration combines the expertise of the undisclosed multinational company in the development and production of microelectromechanical systems (MEMS) with pSivida’s core competency in drug delivery.
